323 related articles for article (PubMed ID: 22472882)
1. PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice.
Shen B; Chu ES; Zhao G; Man K; Wu CW; Cheng JT; Li G; Nie Y; Lo CM; Teoh N; Farrell GC; Sung JJ; Yu J
Br J Cancer; 2012 Apr; 106(9):1486-94. PubMed ID: 22472882
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro.
Yu J; Shen B; Chu ES; Teoh N; Cheung KF; Wu CW; Wang S; Lam CN; Feng H; Zhao J; Cheng AS; To KF; Chan HL; Sung JJ
Hepatology; 2010 Jun; 51(6):2008-19. PubMed ID: 20512989
[TBL] [Abstract][Full Text] [Related]
3. PPARgamma activator rosiglitazone inhibits cell migration via upregulation of PTEN in human hepatocarcinoma cell line BEL-7404.
Zhang W; Wu N; Li Z; Wang L; Jin J; Zha XL
Cancer Biol Ther; 2006 Aug; 5(8):1008-14. PubMed ID: 16775433
[TBL] [Abstract][Full Text] [Related]
4. Activation of peroxisome proliferator-activated receptor-γ (PPARγ) inhibits hepatoma cell growth via downregulation of SEPT2 expression.
Cao LQ; Shao ZL; Liang HH; Zhang DW; Yang XW; Jiang XF; Xue P
Cancer Lett; 2015 Apr; 359(1):127-35. PubMed ID: 25592041
[TBL] [Abstract][Full Text] [Related]
5. A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma.
Kim KR; Choi HN; Lee HJ; Baek HA; Park HS; Jang KY; Chung MJ; Moon WS
Oncol Rep; 2007 Oct; 18(4):825-32. PubMed ID: 17786342
[TBL] [Abstract][Full Text] [Related]
6. Rosiglitazone inhibits metastasis development of a murine mammary tumor cell line LMM3.
Magenta G; Borenstein X; Rolando R; Jasnis MA
BMC Cancer; 2008 Feb; 8():47. PubMed ID: 18261208
[TBL] [Abstract][Full Text] [Related]
7. CITED2 is a novel direct effector of peroxisome proliferator-activated receptor γ in suppressing hepatocellular carcinoma cell growth.
Cheung KF; Zhao J; Hao Y; Li X; Lowe AW; Cheng AS; Sung JJ; Yu J
Cancer; 2013 Mar; 119(6):1217-26. PubMed ID: 23212831
[TBL] [Abstract][Full Text] [Related]
8. Hispidulin inhibits hepatocellular carcinoma growth and metastasis through AMPK and ERK signaling mediated activation of PPARγ.
Han M; Gao H; Ju P; Gao MQ; Yuan YP; Chen XH; Liu KL; Han YT; Han ZW
Biomed Pharmacother; 2018 Jul; 103():272-283. PubMed ID: 29656183
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptor gamma inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells.
Schaefer KL; Wada K; Takahashi H; Matsuhashi N; Ohnishi S; Wolfe MM; Turner JR; Nakajima A; Borkan SC; Saubermann LJ
Cancer Res; 2005 Mar; 65(6):2251-9. PubMed ID: 15781638
[TBL] [Abstract][Full Text] [Related]
10. Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARgamma signaling pathway.
Cao LQ; Wang XL; Wang Q; Xue P; Jiao XY; Peng HP; Lu HW; Zheng Q; Chen XL; Huang XH; Fu XH; Chen JS
Acta Pharmacol Sin; 2009 Sep; 30(9):1316-22. PubMed ID: 19684609
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptor-gamma inhibits transformed growth of non-small cell lung cancer cells through selective suppression of Snail.
Choudhary R; Li H; Winn RA; Sorenson AL; Weiser-Evans MC; Nemenoff RA
Neoplasia; 2010 Mar; 12(3):224-34. PubMed ID: 20234816
[TBL] [Abstract][Full Text] [Related]
12. The insulin receptor: a new anticancer target for peroxisome proliferator-activated receptor-gamma (PPARgamma) and thiazolidinedione-PPARgamma agonists.
Costa V; Foti D; Paonessa F; Chiefari E; Palaia L; Brunetti G; Gulletta E; Fusco A; Brunetti A
Endocr Relat Cancer; 2008 Mar; 15(1):325-35. PubMed ID: 18310298
[TBL] [Abstract][Full Text] [Related]
13. Suppression of pancreatic carcinoma growth by activating peroxisome proliferator-activated receptor gamma involves angiogenesis inhibition.
Dong YW; Wang XP; Wu K
World J Gastroenterol; 2009 Jan; 15(4):441-8. PubMed ID: 19152448
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of Jab1 in hepatocellular carcinoma and its inhibition by peroxisome proliferator-activated receptor{gamma} ligands in vitro and in vivo.
Hsu MC; Huang CC; Chang HC; Hu TH; Hung WC
Clin Cancer Res; 2008 Jul; 14(13):4045-52. PubMed ID: 18593980
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome Proliferator-Activated Receptor γ Expression Is Inversely Associated with Macroscopic Vascular Invasion in Human Hepatocellular Carcinoma.
Hsu HT; Sung MT; Lee CC; Kuo YJ; Chi CW; Lee HC; Hsia CY
Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27483249
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor-γ activation inhibits hepatocellular carcinoma cell invasion by upregulating plasminogen activator inhibitor-1.
Pang X; Wei Y; Zhang Y; Zhang M; Lu Y; Shen P
Cancer Sci; 2013 Jun; 104(6):672-80. PubMed ID: 23461356
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of oxidative stress-elicited AKT activation facilitates PPARγ agonist-mediated inhibition of stem cell character and tumor growth of liver cancer cells.
Liu L; Yang Z; Xu Y; Li J; Xu D; Zhang L; Sun J; Xia S; Zou F; Liu Y
PLoS One; 2013; 8(8):e73038. PubMed ID: 24023668
[TBL] [Abstract][Full Text] [Related]
18. Rosiglitazone enhances 5-fluorouracil-induced cell growth inhibition in hepatocellular carcinoma cell line Hep3B.
Cao LQ; Shao ZL; Peng HP; Xiao JB; Xia T
Chin J Cancer; 2010 Aug; 29(8):741-6. PubMed ID: 20663321
[TBL] [Abstract][Full Text] [Related]
19. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo.
Yu J; Qiao L; Zimmermann L; Ebert MP; Zhang H; Lin W; Röcken C; Malfertheiner P; Farrell GC
Hepatology; 2006 Jan; 43(1):134-43. PubMed ID: 16374840
[TBL] [Abstract][Full Text] [Related]
20. The farnesoid X receptor regulates adipocyte differentiation and function by promoting peroxisome proliferator-activated receptor-gamma and interfering with the Wnt/beta-catenin pathways.
Abdelkarim M; Caron S; Duhem C; Prawitt J; Dumont J; Lucas A; Bouchaert E; Briand O; Brozek J; Kuipers F; Fievet C; Cariou B; Staels B
J Biol Chem; 2010 Nov; 285(47):36759-67. PubMed ID: 20851881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
